{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/epigenetic-moa-drug-development-navigating-regulatory-barriers-enable-hame-study-healthy#webpage",
"url": "https://www.fortrea.com/insights/epigenetic-moa-drug-development-navigating-regulatory-barriers-enable-hame-study-healthy",
"name": "Increasing engagement and collaborative practices in two Phase III oncology trials",
"description": "This Fortrea case study examines the development of a regulatory and clinical pharmacology strategy for an oncology therapy with an epigenetic mechanism of action (MoA) seeking to conduct a human absorption, metabolism and excretion (hAME) study in healthy volunteers. Regulatory concerns regarding genetic pathway modification, the appropriateness of administering epigenetic agents to healthy subjects, and the potential challenges associated with radiolabeled drug administration created significant barriers to study execution. Conducting the hAME study in cancer patients would have introduced additional operational complexities, including hospital-based dosing requirements, patient health considerations, investigational product stability limitations, and logistical risks. Fortrea collaborated with the sponsor to build a scientifically justified feasibility pathway, addressing regulatory concerns through a tailored risk-benefit assessment and clinical pharmacology strategy. The resulting approach supported regulatory review, enabled evaluation of a healthy volunteer study design, reduced operational burden compared with a patient-based hAME study, and helped advance the oncology development program while maintaining scientific and regulatory rigor."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Epigenetic MoA drug development: Navigating regulatory barriers to enable an hAME study in healthy volunteers",
"item": "https://www.fortrea.com/insights/epigenetic-moa-drug-development-navigating-regulatory-barriers-enable-hame-study-healthy"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/epigenetic-moa-drug-development-navigating-regulatory-barriers-enable-hame-study-healthy#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/epigenetic-moa-drug-development-navigating-regulatory-barriers-enable-hame-study-healthy#webpage"
},
"headline": "Epigenetic MoA drug development: Navigating regulatory barriers to enable an hAME study in healthy volunteers| Fortrea Case Study",
"description": "This Fortrea case study examines the development of a regulatory and clinical pharmacology strategy for an oncology therapy with an epigenetic mechanism of action (MoA) seeking to conduct a human absorption, metabolism and excretion (hAME) study in healthy volunteers. Regulatory concerns regarding genetic pathway modification, the appropriateness of administering epigenetic agents to healthy subjects, and the potential challenges associated with radiolabeled drug administration created significant barriers to study execution. Conducting the hAME study in cancer patients would have introduced additional operational complexities, including hospital-based dosing requirements, patient health considerations, investigational product stability limitations, and logistical risks. Fortrea collaborated with the sponsor to build a scientifically justified feasibility pathway, addressing regulatory concerns through a tailored risk-benefit assessment and clinical pharmacology strategy. The resulting approach supported regulatory review, enabled evaluation of a healthy volunteer study design, reduced operational burden compared with a patient-based hAME study, and helped advance the oncology development program while maintaining scientific and regulatory rigor.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2026-02/epigenetic-hame.png.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-02-11",
"dateModified": "2026-02-11",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-02/epigenetic-moa-hame.pdf.pdf",
"encodingFormat": "application/pdf"
}
}
]
}